241 known responders to nabiximols treatment with multiple sclerosis received nabiximols (2.7 mg THC and 2.5 mg CBD per 100-uL actuation) treatment for 4 weeks, and were then randomized to receive either titrated doses of nabiximols or placebo through an oralmucosal spray over 12 weeks. The purpose of the study was to determine whether Nabiximols is associated with significantly better spasticity numeric rating scores (NRS), spasm frequency, sleep disruptions, and quality of life compared to placebo. Results indicate that Nabiximols significantly better improvements in mean spasticity NRS scores, spasm frequency, sleep disruption and several quality of life measures compared to placebo, while maintaining a similar rate of adverse events.